• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Natural Products
    CAS No. 51-55-8 Price $30 / 20mg
    Catalog No.CFN98824Purity>=98%
    Molecular Weight289.4 Type of CompoundAlkaloids
    FormulaC17H23NO3Physical DescriptionPowder
    Download Manual    COA    MSDSSimilar structuralComparison (Web)
    Citing Use of our Products
    How to Order
    Orders via your E-mail:

    1. Product number / Name / CAS No.
    2. Delivery address
    3. Ordering/billing address
    4. Contact information
    Sent to Email: info@chemfaces.com
    Contact Us
    Order & Inquiry & Tech Support

    Tel: (0086)-27-84237683
    Fax: (0086)-27-84254680
    E-mail: manager@chemfaces.com
    Address: No. 83, CheCheng Rd., WETDZ, Wuhan, Hubei 430056, PRC
    Delivery time
    Delivery & Payment method

    1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

    2. We accept: Wire transfer & Credit card & Paypal & Western Union
    * Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
    According to end customer requirements, ChemFaces provide solvent format. This solvent format of product intended use: Signaling Inhibitors, Biological activities or Pharmacological activities.
    Size /Price /Stock 10 mM * 1 mL in DMSO / $19.7 / In-stock
    Other Packaging *Packaging according to customer requirements(100uL/well, 200uL/well and more), and Container use Storage Tube With Screw Cap
    Our products had been exported to the following research institutions and universities, And still growing.
  • Universidad de Ciencias y Artes... (Mexico)
  • Universidad de Buenos Aires (Argentina)
  • Srinakharinwirot University (Thailand)
  • Universitas islam negeri Jakarta (Indonesia)
  • The Vancouver Prostate Centre (... (Canada)
  • Charles Sturt University (Denmark)
  • University of Padjajaran (Indonesia)
  • Universiti Putra Malaysia(UPM) (Malaysia)
  • University of the Basque Country (Spain)
  • Universidade Federal de Goias (... (Brazil)
  • University of Perugia (Italy)
  • More...
  • Package
    Featured Products

    Catalog No: CFN98757
    CAS No: 482-39-3
    Price: $288/20mg

    Catalog No: CFN97049
    CAS No: 61303-13-7
    Price: $178/20mg
    Sikokianin A

    Catalog No: CFN92155
    CAS No: 106293-99-6
    Price: $433/5mg
    Ganoderol B

    Catalog No: CFN99064
    CAS No: 104700-96-1
    Price: $368/5mg

    Catalog No: CFN92287
    CAS No: 81446-29-9
    Price: $268/5mg

    Catalog No: CFN99883
    CAS No: 19103-54-9
    Price: $338/10mg
    Rebaudioside B

    Catalog No: CFN90470
    CAS No: 58543-17-2
    Price: $238/20mg
    Related Screening Libraries
    Size /Price /Stock 10 mM * 100 uL in DMSO / Inquiry / In-stock
    10 mM * 1 mL in DMSO / Inquiry / In-stock
    Related Libraries
  • Myopia treatment Compound Library
  • Antagonists Compound Library
  • Alkaloids Compound Library
  • AChR Inhibitor Library
  • Biological Activity
    Description: Atropine is a competitive antagonist of the muscarinic acetylcholine receptors (acetylcholine being the main neurotransmitter used by the parasympathetic nervous system), used to treat certain types of nerve agent and pesticide poisonings, some types of slow heart rate, and to decrease saliva production during surgery.
    Targets: AChR
    In vitro:
    J Pediatr Ophthalmol Strabismus. 2014 Nov-Dec;51(6):363-9.
    Use of atropine penalization to treat amblyopia in UK orthoptic practice.[Pubmed: 25427306]
    To compare clinical practice patterns regarding Atropine penalization use by UK orthoptists to the current evidence base and identify any existing barriers against use of AP as first-line treatment.
    An online survey was designed to assess current practice patterns of UK orthoptists using Atropine penalization. They were asked to identify issues limiting their use of Atropine penalization and give opinions on its effectiveness compared to occlusion. Descriptive statistics and content analysis were applied to the results. Responses were obtained from 151 orthoptists throughout the United Kingdom. The main perceived barriers to use of Atropine penalization were inability to prescribe Atropine and supply difficulties. However, respondents also did not consider Atropine penalization as effective as occlusion in treating amblyopia, contrary to recent research findings. Patient selection criteria and treatment administration largely follow current evidence. More orthoptists use Atropine penalization as first-line treatment than previously reported.
    CONCLUSIONS: Practitioners tend to closely follow the current evidence base when using Atropine penalization, but reluctance in offering it as first-line treatment or providing a choice for parents between occlusion and Atropine still remains.
    This may result from concerns regarding Atropine's general efficacy, side effects, and risk of reverse amblyopia. Alternatively, as demonstrated in other areas of medicine, it may reflect the inherent delay of research findings translating to clinical practice changes.
    In vivo:
    J Community Support Oncol. 2015 Jan;13(1):3-7.
    Use of atropine-diphenoxylate compared with hyoscyamine to decrease rates of irinotecan-related cholinergic syndrome.[Pubmed: 25839059]
    To compare the incidence of cholinergic syndrome with irinotecan using Atropine-diphenoxylate or hyoscyamine as premedication.
    We conducted a retrospective, single-center, nonrandomized, cohort study of adult patients treated with Atropine-diphenoxylate or hyoscyamine as premedication before receiving irinotecan. For all irinotecan infusions, intravenous Atropine was administered for patients experiencing any cholinergic reaction. A total of 532 irinotecan cycles (354 cycles for Atropine-diphenoxylate group; 178 cycles for hyoscyamine group) were analyzed in 80 patients. Overall incidence of cholinergic syndrome did not differ between Atropine-diphenoxylate (8.2%) and hyoscyamine (9.0%) groups (P = .76). The incidence of cholinergic syndrome after the £rst cycle of irinotecan was similar between the 2 arms, Atropine-diphenoxylate (14.6%) and hyoscyamine (10.7%), with P = .74. The most common cholinergic symptoms documented were abdominal pain or cramping, and diarrhea. This study was subjected to vulnerabilities to bias and random error because of its observational retrospective design and small number of participants.
    Lack of difference in the incidence of cholinergic syndrome observed in irinotecan-treated patients suggests Atropinediphenoxylate and hyoscyamine may both be effective prophylactic options. The findings support the need for a larger, randomized study to assess and compare these agents with other potential premedications such as scopolamine and Atropine in prevention of irinotecan-related cholinergic syndrome.
    Ther Adv Cardiovasc Dis. 2014 Oct;8(5):176-84.
    Atropine first is safer than conventional atropine administration in older people undergoing dobutamine stress echocardiography.[Pubmed: 24906705]
    Early injection of Atropine during dobutamine stress echocardiography (DSE) has been demonstrated in retrospective analyses to reduce the duration and dose of dobutamine infusion, while preserving a similar diagnostic accuracy with a lower incidence of adverse effects. This study explores the safety of using Atropine as a start drug before dobutamine infusion (ADSE protocol) in comparison with the conventional protocol (DASE protocol) in older patients undergoing DSE for ischemia evaluation.
    One hundred consecutive older patients were prospectively enrolled. When eligible, they were randomly assigned to undergo either the DASE protocol (group A, 50 patients) or the ADSE protocol (group B, 50 patients) when Atropine (1.0 mg) was first administered 3 min before dobutamine infusion followed by 0.5 mg increments (maximum 1.0 mg) thereafter. Patients were monitored for adverse drug effects. Test duration was calculated. The mean age of the whole study cohort was 67.8±4.3 years and 58 (58%) were men. Patients in group A had longer test duration (21.8±1.3 versus 13.7±0.77 min, p<0.001) and higher mean dobutamine infusion rate (39±8.2 versus 28.2±9.5 μg/kg/min, p<0.001). The two groups received a similar total dose of Atropine. Group A patients showed significantly higher incidence of extrasystoles, nonsustained ventricular tachycardia and severe hypotension (p<0.05).
    In older patients undergoing DSE, using Atropine as a start drug, that is, adopting the ADSE protocol, is associated with shorter test duration, lower mean dobutamine infusion rate and consequently fewer adverse effects.
    Atropine Description
    Source: The herbs of Atropa belladonna L.
    Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
    Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

    After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
    Recent ChemFaces New Products and Compounds
    Poricoic acid G

    Catalog No: CFN95056
    CAS No: 415724-84-4
    Price: $318/5mg

    Catalog No: CFN95063
    CAS No: 161099-37-2
    Price: $333/5mg
    Ganoderic acid C6

    Catalog No: CFN92290
    CAS No: 105742-76-5
    Price: $368/10mg

    Catalog No: CFN98531
    CAS No: 27210-57-7
    Price: $288/5mg
    Isorubrofusarin 10-gentiobioside

    Catalog No: CFN95119
    CAS No: 200127-93-1
    Price: $338/10mg
    Ganoderic acid B

    Catalog No: CFN92052
    CAS No: 81907-61-1
    Price: $328/10mg
    Cistantubuloside C1

    Catalog No: CFN95121
    CAS No: 620632-36-2
    Price: $298/10mg
    Shancigusin I

    Catalog No: CFN95061
    CAS No: 1435488-35-9
    Price: $388/5mg
    Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.

    PMID: 30417089
    Calculate Dilution Ratios(Only for Reference)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 3.4554 mL 17.2771 mL 34.5543 mL 69.1085 mL 86.3856 mL
    5 mM 0.6911 mL 3.4554 mL 6.9109 mL 13.8217 mL 17.2771 mL
    10 mM 0.3455 mL 1.7277 mL 3.4554 mL 6.9109 mL 8.6386 mL
    50 mM 0.0691 mL 0.3455 mL 0.6911 mL 1.3822 mL 1.7277 mL
    100 mM 0.0346 mL 0.1728 mL 0.3455 mL 0.6911 mL 0.8639 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.